US Imposes 26% Reciprocal Tariff on India: Sector-by-Sector Impact Analysis
On April 2, 2026 — dubbed "Liberation Day" by US President Donald Trump — the United States announced a sweeping set of "reciprocal tariffs" on imports from all major trading partners. India was assigned a 26% tariff rate on its goods exported to the US.
The tariff announcement is framed by the US as a response to what it calls asymmetric trade barriers — India's average applied tariff on US goods (around 12–13%) compared to the US average tariff on Indian goods (around 3%).
Pharmaceutical exports from India (~USD 12.2 billion annually to the US) were initially exempted from the tariffs — a significant relief, as India supplies ~45% of US generic drug imports.
The IT services sector faces indirect pressure: fears of a US recession triggered by the trade war could reduce discretionary corporate spending on IT outsourcing, hurting Indian IT firms. Nifty IT fell over 3% on April 2.
Textiles face a mixed outcome: India's 26% tariff compares favourably with Vietnam (46%), Bangladesh (37%), Cambodia (49%), and Pakistan (30%) — potentially diverting orders to Indian exporters.
Automobiles, gems and jewellery, and some agriculture products face direct headwinds from the higher tariff wall.
India's total merchandise exports to the US in FY25 were approximately USD 77 billion, making the US India's single largest export destination.
Reciprocal Tariffs: Concept and US Trade Policy History
A "reciprocal tariff" is a tariff designed to match the rate charged by a trading partner — a form of tit-for-tat trade policy. The theoretical basis is "tariff reciprocity," used in WTO negotiations where countries exchange tariff concessions. However, President Trump's "Liberation Day" use of reciprocal tariffs departs from this framework: the US calculated partner tariff rates using a formula based on trade deficit magnitude rather than actual tariff comparisons, drawing criticism for methodological flaws. Historically, the US has used the International Emergency Economic Powers Act (IEEPA) and Section 301 of the Trade Act of 1974 to impose unilateral tariffs outside the WTO framework.
The 26% tariff on India is calculated using the trade-deficit formula, not India's actual tariff rate — meaning India is being penalised for the bilateral goods trade deficit with the US, regardless of service trade surplus or investment flows.
India-US Trade Relationship: Structure and Significance
India-US bilateral trade in goods reached approximately USD 130 billion in FY25, with India running a goods trade surplus (~USD 45 billion). In services, India has a surplus exceeding USD 30 billion (primarily IT/ITeS exports). The US has been India's top merchandise export destination since 2021. Key Indian exports to the US: pharma (USD 12.2B), gems/jewellery (USD 9B), IT hardware/software (USD 8B), textiles/apparel (USD 7B), engineering goods, petroleum products, chemicals. Key US exports to India: petroleum, machinery, aircraft, defence equipment, electronic components.
The 26% tariff targets India's goods exports but does not cover services — meaning India's USD 75 billion IT services trade is not directly affected, though a US recession caused by the tariff war would reduce demand for Indian IT services indirectly.
India's Export Competitiveness: Sector-Specific Analysis
India's relative tariff position compared to competing exporters determines whether the 26% tariff represents a competitive advantage or disadvantage. In labour-intensive sectors (textiles, footwear, garments), India's 26% compares favourably to Vietnam (46%), Bangladesh (37%), and Cambodia (49%) — suggesting potential order diversion to India. In pharmaceuticals, the initial exemption protects India's most valuable export segment. In IT services (delivered digitally), tariffs are irrelevant; demand contraction is the risk. In gems/jewellery and engineering goods, the 26% tariff makes Indian goods more expensive for US buyers, potentially reducing volumes.
The "one battle after another" framing captures a multi-front trade challenge: the US tariffs create both risks (for pharma if exemption ends, IT if US economy slows) and opportunities (textiles gaining competitive edge over higher-tariffed Asian rivals).
- US tariff on India: 26% (announced April 2, 2026, "Liberation Day")
- India's merchandise exports to US (FY25): ~USD 77 billion (top export destination)
- Pharma exports to US: ~USD 12.2 billion (initially exempted from tariffs)
- India supplies ~45% of US generic drug imports
- US tariff on key competitors: Vietnam 46%, Bangladesh 37%, Cambodia 49%, Pakistan 30%, China 54%+
- India's average MFN tariff on US goods: ~12–13%; US on India: previously ~3.4%
- Nifty IT fell over 3% on April 2, 2026 on recession fears
- India-US goods trade surplus (India's): ~USD 45 billion in FY25
- Legal basis for US tariffs: International Emergency Economic Powers Act (IEEPA)